IL1RA antagonist protein (Active) (ab83761)
Constituents: 10% Trehalose, 1% Human serum albumin
Our Abpromise guarantee covers the use of ab83761 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
pI: ab83761 separates into a number of isoforms with a pI between 5.4 and 6.3 in 2D PAGE due to post-translational modifications, in particular glycosylation. This compares with the unmodified IL1RA that has a predicted pI of 5.4.
Molecular Mass: ab83761 migrates as a broad band between 18 and 23 kDa in SDS-PAGE due to post-translation modifications, in particular glycosylation. This compares with the unmodified IL1RA that has a predicted molecular mass of 17.1 kDa. ab83761 consists of 5-25% carbohydrate by weight.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- DIRAICIL 1RAICIL-1RA
- ICIL1RAIL-1raIL-1ra3IL-1RNIL1 inhibitorIL1F3IL1RAIL1RA_HUMANIL1RNIL1RN (IL1F3)Interleukin 1 receptor antagonistInterleukin-1 receptor antagonist proteinIntracellular IL 1 receptor antagonist type IIIntracellular interleukin 1 receptor antagonist (icIL 1ra)IRAPMGC10430MVCD4Type II interleukin 1 receptor antagonist
Defects in IL1RN are the cause of interleukin 1 receptor antagonist deficiency (DIRA) [MIM:612852]; also known as deficiency of interleukin 1 receptor antagonist. Autoinflammatory diseases manifest inflammation without evidence of infection, high-titer autoantibodies, or autoreactive T-cells. DIRA is a rare, autosomal recessive, genetic autoinflammatory disease that results in sterile multifocal osteomyelitis (bone inflammation in multiple places), periostitis (inflammation of the membrane surrounding the bones), and pustulosis (due to skin inflammation) from birth.
IL1RA antagonist protein (Active) images
Densitometry of protein isoforms visualised by 2-DE.
The densitometry scan demonstrates the purified human cell expressed protein exists in multiple isoforms, which differ according to their level of post-translational modification.
The triangle indicates the theoretical MW and pI of the protein.
1D SDS-PAGE of ab83761 before and after treatment with glycosidases to remove oligosaccharides.
Lane 1: ab83761
Lane 2: ab83761 treated with PNGase F to remove potential N-linked glycans.
Lane 3: ab83761 treated with a glycosidase cocktail to remove potential N- and O-linked glycans.
10 µg protein loaded per lane. Drop in MW after treatment with PNGase F indicates the presence of N-linked glycans. Faint bands in lane 3 and lane 4 are glycosidase enzymes.
References for IL1RA antagonist protein (Active) (ab83761)
ab83761 has not yet been referenced specifically in any publications.